NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
- State
- Under way
- Phase
- Phase 3
- People
- 1,500 planned
- Started
- 11 Oct 2023
- Primary completion
- Apr 2030
- Arms
- Study 1: Group 1 Upadacitinib Dose A, Study 1: Group 2 Upadacitinib Dose B, Study 2: Group 1 Upadacitinib Dose A, Study 2: Group 2 Upadacitinib Dose B, Study 3: Group 1 Upadacitinib Dose B (SALT > 20), Study 3: Group 2 Upadacitinib Dose A (SALT ≤ 20), Study 3: Group 3 Upadacitinib Dose B (Non-Sustained), Study 3: Group 4 Upadacitinib Dose B (Sustained), Study 3: Group 5 Upadacitinib Dose A (Sustained), Study 4: Group 1 Upadacitinib Dose A, Study 4: Group 2 Upadacitinib Dose B, Study 4: Group 4 Upadacitinib Dose A, Study 4: Group 5 Upadacitinib Dose B
- Results
- None posted
- Papers
- doi:10.1001/jamadermatol.2026.2853
- 25 Aug 2023: Trial registered
- 11 Oct 2023: Trial started